MSD Releases Statement on NICE Publication HTTA329 on Introducing Biosimilars of Infliximab

MSD Releases Statement on NICE Publication HTTA329 on Introducing Biosimilars of Infliximab
Last July 2015, NICE published HTTA329 as a reference for select NHS organizations in the UK that are currently planning to join the market with their own biosimilar products for the treatment of a wide range of diseases, including Inflammatory Bowel Disease. The MSD, which operates in over 140 countries and to provide prescription medicines, vaccines, biologic therapies,

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *